@article{6886b07306984c14981c2dade9f33607,
title = "What is good mental health? A scoping review",
abstract = "Promotion of good mental health in young people with and without mental disorders has received little empirical research attention and interventions for improving mental health in young people are not well established. This situation could be explained among other reasons due to the difficulties to define and operationalise what good mental health is. The current manuscript, produced by the European College of Neuropsychopharmacology Thematic Working Group on the Prevention of Mental Disorders and Mental Health Promotion (ECNP TWG PMD-MHP), presents a critical review of the available operationalizations for good mental health. A pragmatic conceptual operationalisation of good mental health is a much-needed step towards more standardised research in this field.Good mental health can be defined as a state of well-being that allows individuals to cope with the normal stresses of life and function productively. Universal and selective interventions are suitable to promote mental health. Core domains that define good mental health encompass: (i) mental health literacy, (ii) attitude towards mental disorders, (iii) self-perceptions and values, (iv) cognitive skills, (v) academic/ occupational performance, (vi) emotions, (vii) behaviours, (viii) self-management strategies, (ix) social skills, (x) family and significant relationships (xi) physical health, (xii) sexual health, (xiii) meaning of life, (xiv) and quality of life. These domains should be widely traceable in the literature and can be used to conduct further empirical research in the field of good mental health. Such data can lead to more robust evidence to identify and establish the pathways to follow in order to improve mental health. (C) 2020 The Authors. Published by Elsevier B.V.",
keywords = "bipolar disorder, chinese version, clinical high-risk, evidence-based medicine, good mental health, health promotion, help-seeking, initial validation, interventions, prevention, psychometric properties, public health, quality-of-life, school-children, social-skills, ultra-high risk, HELP-SEEKING, Evidence-based medicine, Prevention, SOCIAL-SKILLS, QUALITY-OF-LIFE, Public health, CLINICAL HIGH-RISK, PSYCHOMETRIC PROPERTIES, Health promotion, ULTRA-HIGH RISK, SCHOOL-CHILDREN, BIPOLAR DISORDER, INITIAL VALIDATION, Good mental health, Interventions, CHINESE VERSION",
author = "P. Fusar-Poli and {de Pablo}, G.S. and {De Micheli}, A. and D.H. Nieman and C.U. Correll and L.V. Kessing and A. Pfennig and A. Bechdolf and S. Borgwardt and C. Arango and {van Amelsvoort}, T.",
note = "Funding Information: The study was supported by the European College of Neuropsychopharmacology Network Taskforce. Dr. Salazar de Pablo is supported by the Alicia Koplowitz Foundation. Funding Information: Dr. Fusar-Poli has been a consultant to or has received honoraria or grants from Lundbeck, Menarini, Boehringer Ingelheim. Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. Dr. Kessing has been a consultant to or has received honoraria or grants from Lundbeck. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Bechdolf has been a consultant and/or advisor to or has received honoraria or grants from: Janssen/J&J, LB Pharma, Lundbeck, Otsuka, Pfizer and Recordati. Funding Information: The study was supported by the European College of Neuropsychopharmacology Network Taskforce. Dr. Salazar de Pablo is supported by the Alicia Koplowitz Foundation. PFP designed the study. PFP and GSP drafted the manuscript. DN, CUC, LVK, AP, AB, SB, CA and TVA revised the manuscript and provided a substantial conceptual contribution. All authors proofread and approved the final draft of the manuscript. The authors declare that there are no conflicts of interest in relation to the subject of this study. Dr. Fusar-Poli has been a consultant to or has received honoraria or grants from Lundbeck, Menarini, Boehringer Ingelheim. Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. Dr. Kessing has been a consultant to or has received honoraria or grants from Lundbeck. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Bechdolf has been a consultant and/or advisor to or has received honoraria or grants from: Janssen/J&J, LB Pharma, Lundbeck, Otsuka, Pfizer and Recordati. Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
month = feb,
day = "1",
doi = "10.1016/j.euroneuro.2019.12.105",
language = "English",
volume = "31",
pages = "33--46",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
}